Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 41,200 shares, a growth of 396.4% from the December 15th total of 8,300 shares. Currently, 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 27,200 shares, the short-interest ratio is currently 1.5 days.
Dominari Trading Down 4.6 %
Shares of Dominari stock traded down $0.05 during trading hours on Monday, reaching $1.04. The stock had a trading volume of 39,688 shares, compared to its average volume of 81,185. Dominari has a twelve month low of $0.83 and a twelve month high of $3.20. The firm has a market capitalization of $6.59 million, a PE ratio of -0.27 and a beta of 1.03. The stock’s 50 day moving average is $1.46 and its 200 day moving average is $1.68.
Dominari (NASDAQ:DOMH – Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.45) EPS for the quarter. Dominari had a negative net margin of 180.22% and a negative return on equity of 32.89%. The business had revenue of $4.04 million during the quarter.
Dominari Company Profile
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
See Also
- Five stocks we like better than Dominari
- Using the MarketBeat Dividend Yield Calculator
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What is an Earnings Surprise?
- Delta Can Fly to New Highs in 2025; Here’s Why
- What Are Dividend Champions? How to Invest in the Champions
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.